New York – July 2, 2019 – As one of the global leading chemical suppliers, BOC Sciences newly releases an important inhibitor eribulin (CAS 253128-41-5) intended for research use for scientists in both academic and industrial circle. Meanwhile, another 80 inhibitors that also target microtubule and tubulin have also been released in the past two months, such as mertansine, epothilone D and nocodazole.
Eribulin, also known as E7389 and ER-086526, is a non-taxane microtubule inhibitor and has been developed into a chemotherapy drug under the name of Halaven® for the treatment of breast cancer and liposarcoma, which is a type of soft tissue sarcoma. Also, it may also be used to treat a variety of other solid tumors, including non-small cell lung cancer, prostate cancer and sarcoma.
“In 2010 and 2011, eribulin was approved by U.S. Food and Drug Administration and Health Canada, respectively, for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens,” says Prof. Jones, a senior scientist from BOC Sciences. “Ever since then, the research on broadening the therapeutic effects of eribulin has never ceased. In 2018, FDA approved eribulin for the treatment of inoperable liposarcoma in patients who received prior chemotherapy that contained an anthracycline drug. And a remarkable increase in the overall survival rate has been observed in phase III trial.”
As a laboratory-made substance, eribulin is found to be derived from a sea sponge. Similar to some other chemotherapy drugs, it targets the protein tubulin in cells. However, it binds to tubulin in a different way, interfering with cancer cell division and growth. Interestingly, it has both cytotoxic and non-cytotoxic mechanisms of action. In terms of cytotoxic effects, its antimitotic activities are intensively researched. On the other hand, preclinical studies in human breast cancer models have shown that eribulin also exerts complex effects on the biology of surviving cancer cells and residual tumors that appear unrelated to its antimitotic effects.
Research on eribulin is also ongoing. “Two new eribulin based products are in the research and development phase. One is a liposomal formulation and the other is an antibody drug combination therapy. Both are for the treatment of solid tumors,” adds Prof. Jones. “The liposomal formulation of eribulin, E7389 liposomal, is currently in Phase 1 clinical trials, while the combination therapy of eribulin and pembrolizumab is intended for the treatment of breast cancer and other advanced cancers.”
For scientists involved with relevant research, almost 80 small molecule inhibitors that target microtubule and tubulin are now available at BOC Sciences, and more could be added as time passes by when new demands arise.
For more information about eribulin, please visit https://www.bocsci.com/eribulin-cas-253128-41-5-item-305436.html.
About BOC Sciences
For the last two decades, BOC Sciences has been a trust-worthy vendor supplying a comprehensive collection of chemicals to researchers, such as inhibitors, metabolites, impurities and natural compounds. And at the same time, it also provides a wide range of services and technology platforms that cover all stages of drug R&D to support the pharmaceutical industry, including custom synthesis of chemicals, isotope labeling, formulation service, targeted protein degradation platform, antibody drug conjugates, chiral synthesis and resolution.
Company Name: BOC Sciences
Contact Person: Alex Brown
Email: Send Email
Phone: 1631 619 7922
Address:45-16 Ramsey Road, Shirley
State: NY 11967
Country: United States